NFE2L2 and diabetic kidney disease: In another study, Li et al. demonstrated the ability of apigenin nanoparticles to reduce renal damage associated with diabetic kidney disease through activation of Nrf2/HO-1 and inhibition of the NF-κB signaling pathway [188] (Figure 3).